The Technical Analyst
BioAtla, Inc. [BCAB]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BioAtla, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
7.11% $2.41
America/New_York / 26 apr 2024 @ 13:01
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 115.91 mill |
| EPS: | -2.47 |
| P/E: | -0.980 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 48.10 mill |
| Avg Daily Volume: | 0.549 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.980 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.17x |
| Company: PE -0.980 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$2.28 (-5.33%) $-0.128 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.09 - 2.71 ( +/- 13.08%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-31 | Smith Scott Andrew | Sell | 2 181 | Common Stock |
| 2024-03-31 | Sievers Eric | Sell | 572 | Common Stock |
| 2024-02-29 | Smith Scott Andrew | Sell | 2 181 | Common Stock |
| 2024-02-29 | Sievers Eric | Sell | 572 | Common Stock |
| 2024-02-15 | Waldron Richard A | Buy | 106 000 | Common Stock |
| INSIDER POWER |
|---|
| 93.82 |
| Last 100 transactions |
| Buy: 3 003 180 | Sell: 92 181 |
Forecast:
14:40 - $2.42
Live Trading Signals (every 1 min)
Forecast
1: 13:10 - $2.40
Forecast 2: 14:00 - $2.42
Forecast 3: 14:40 - $2.42
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.41 (7.11% ) |
| Volume | 0.133 mill |
| Avg. Vol. | 0.549 mill |
| % of Avg. Vol | 24.27 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BCAB
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $2.92 | N/A | Active |
|---|
BCAB
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Latest Press Releases
2024-04-24 16:35:00 - Press Release
Bioatla Announces Upcoming Poster Presentation At The 2024 American Society Of Clinical Oncology (asco) Annual Meeting
San diego, april 24, 2024 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2024 american society of clinical oncology (asco) annual meeting to be held virtually and at the mccormick place convention center in chicago, illinois from may 31–june 4, 2024.
2024-03-26 16:01:00 - Press Release
Bioatla Reports Fourth Quarter And Full Year 2023 Financial Results And Highlights Recent Progress
San diego, march 26, 2024 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the fourth quarter and full year ended december 31, 2023, and provided highlights on its clinical programs.
2024-03-19 08:00:00 - Press Release
Bioatla To Announce Fourth Quarter And Full-year 2023 Financial Results And Provide Business Highlights On March 26, 2024
San diego, march 19, 2024 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on tuesday, march 26, 2024 at 4:30 p.m. et to discuss its financial results for the fourth quarter and full-year ended december 31, 2023 and provide business highlights.
2024-03-07 08:00:00 - Press Release
Bioatla Announces Poster Presentations At The 2024 American Association For Cancer Research (aacr) Annual Meeting
San diego, march 07, 2024 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today announced preclinical poster presentations at the upcoming 2024 american association for cancer research (aacr) annual meeting to be held at the san diego convention center in san diego, california from april 5–10, 2024.
2023-12-20 08:00:00 - Press Release
Bioatla To Participate In The 42nd Annual J.p. Morgan Healthcare Conference
San diego, dec. 20, 2023 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today announced that the company's management will participate in a fireside chat and one-on-one investor meetings at the 42nd annual j.p. morgan healthcare conference, to be held in san francisco, ca january 8-11, 2024.
Latest News
2024-03-19 08:00:00 - GlobeNewsWire
BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, March 26, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2023 and provide business highlights.
2023-11-12 05:38:07 - Seeking Alpha
BioAtla, Inc. (BCAB) Q3 2023 Earnings Call Transcript
BioAtla, Inc. (NASDAQ:BCAB ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Bruce Mackle - Investor Relations, LifeSci Advisors, LLC Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief Financial Officer Eric Sievers - Chief Medical Officer Conference Call Participants Brian Cheng - JPMorgan Kaveri Pohlman - BTIG Dev Prasad - Jefferies Arthur He - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the BioAtla Third Quarter 2023 Earnings Call.
2023-10-10 07:30:00 - GlobeNewsWire
BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023
SAN DIEGO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today provided guidance on near-term milestones and announced that it plans to host a conference call and webcast on Tuesday, November 7, 2023 at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2023 and provide business highlights.
2023-09-06 08:00:00 - GlobeNewsWire
BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management will provide a corporate update and participate virtually in scheduled one-on-one investor meetings at the H.C. Wainwright 25th Annual Global Investment Conference, to be held September 11-13, 2023.
2023-08-03 16:01:00 - GlobeNewsWire
BioAtla to Participate in Upcoming Investor Conferences in August
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management will participate in two upcoming investor conferences, to be held in August 2023.
2023-08-01 23:18:02 - Seeking Alpha
BioAtla, Inc. (BCAB) Q2 2023 Earnings Call Transcript
BioAtla, Inc. (NASDAQ:BCAB ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Bruce Mackle - IR, LifeSci Advisors, LLC Jay Short - Chairman & Chief Medical Officer Richard Waldron - Chief Financial Officer Eric Sievers - Chief Medical Officer Sheri Lydick - Chief Commercial Officer Conference Call Participants Brian Cheng - JPMorgan Kaveri Pohlman - BTIG Arthur He - H.C. Wainwright Tony Butler - E.F.
2023-07-25 08:00:00 - GlobeNewsWire
BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023
SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, August 1, 2023 at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2023 and provide business highlights.
2023-05-11 22:51:02 - Seeking Alpha
BioAtla, Inc. (BCAB) Q1 2023 Earnings Call Transcript
BioAtla, Inc. (NASDAQ:BCAB ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Bruce Mackle - IR, LifeSci Advisors, LLC Jay Short - Chairman and CEO Richard Waldron - CFO Philippe Martin - Chief CDO Conference Call Participants Brian Cheng - JPMorgan Kaveri Pohlman - BTIG Reni Benjamin - JMP Securities Arthur He - H.C. Wainwright Operator Greetings.
2023-05-04 08:00:00 - GlobeNewsWire
BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023
SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, May 11, 2023 at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2023 and provide business highlights.
2023-03-23 22:33:04 - Seeking Alpha
BioAtla, Inc. (BCAB) Q4 2022 Earnings Call Transcript
BioAtla, Inc. (NASDAQ:BCAB ) Q4 2022 Earnings Call Transcript March 23, 2023 4:30 PM ET Company Participants Bruce Mackle - Investor Relations, LifeSci Advisors, LLC Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief Financial Officer Philippe Martin - Chief Clinical Development and Operations Conference Call Participants Brian Cheng - JPMorgan Kelly Shi - Jefferies Tony Buter - EF Hutton Arthur He - H.C. Wainwright Reni Benjamin - JMP Securities Operator Greetings.